Abera Bioscience AB is a biotechnology company based in Stockholm, specializing in the development of next-generation mucosal vaccines. The company focuses on creating novel vaccine platforms designed to enhance efficacy, particularly in addressing global health challenges. Abera has an active vaccine pipeline that targets various diseases, with a notable emphasis on vaccines for influenza and pneumococcal infections.
The company has reported promising long-term data for its nasal influenza vaccine, demonstrating strong and sustained immune responses in preclinical studies. Additionally, Abera has been awarded a grant from BactiVac to support its research initiatives. One of its ongoing studies involves a spray applicator for the pneumococcal vaccine Ab-01.12, which reflects the company's commitment to combating future pandemics through innovative vaccine solutions. Abera also contributes to the scientific community with research articles focused on influenza and pneumococcal vaccines.